(2S,3S,4R,5R)-5-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4R,5S,6R)-3-acetamido-4-hydroxy-6-methyl-5-[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-[(2-hydroxy-5-oxocyclopenten-1-yl)carbamoyl]oxan-2-yl]oxyoxan-2-yl]oxy-4-hydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-4-carbamoyloxy-3,6-dihydroxy-3-methyloxane-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2S,3S,4R,5R)-5-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4R,5S,6R)-3-acetamido-4-hydroxy-6-methyl-5-[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-[(2-hydroxy-5-oxocyclopenten-1-yl)carbamoyl]oxan-2-yl]oxyoxan-2-yl]oxy-4-hydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-4-carbamoyloxy-3,6-dihydroxy-3-methyloxane-2-carboxylic acid
• 化学式: C₄₁H₆₂N₄O₂₉
• 分子量: 1074.9
• InChiKey: FTZOLITWXQXOED-GFBAXCRRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -8.8
• 重原子数：
  74
• 可旋转键数：
  17
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  520
• 氢给体数：
  17
• 氢受体数：
  29

文献信息

• Anionic Conjugates of Glycosylated Bacterial Metabolite
  申请人：GLYCAN BIOSCIENCES LLC

  公开号：US20140323422A1

  公开（公告）日：2014-10-30

  The invention relates to anionic conjugates of glycosylated bacterial metabolites that may be used to mimic the structure and/or activity of the anionic bioactive molecules known as glycosaminoglycans (GAGs). The invention also relates to processes for the preparation of the conjugates. Such conjugates are useful in the prophylaxis and/or treatment of disease conditions and in particular chronic disease conditions such as inflammatory (including allergic) diseases, metastatic cancers and infection by pathogenic agents including bacteria, viruses or parasites.
• ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE
  申请人：GLYCAN BIOSCIENCES LLC

  公开号：US20160303243A1

  公开（公告）日：2016-10-20

  The invention relates to anionic conjugates of glycosylated bacterial metabolites that may be used to mimic the structure and/or activity of the anionic bioactive molecules known as glycosaminoglycans (GAGs). The invention also relates to processes for the preparation of the conjugates. Such conjugates are useful in the prophylaxis and/or treatment of disease conditions and in particular chronic disease conditions such as inflammatory (including allergic) diseases, metastatic cancers and infection by pathogenic agents including bacteria, viruses or parasites.
• US8791245B2
  申请人：——

  公开号：US8791245B2

  公开（公告）日：2014-07-29
• US9346845B2
  申请人：——

  公开号：US9346845B2

  公开（公告）日：2016-05-24